Similarly, nonseminomatous tumor patients with high SLC5A5 expression exhibited a twofold increased recurrence risk (p = 0.061, HR = 2.31, 95% CI: 0.961–5.537) (Figure 3c). Here, SLC5A5 is linked to neoplasm.